Table 1. Patients’ and disease characteristics.
| Patients, % | ||||
|---|---|---|---|---|
| Age < 65 N=249 (%) |
Age 65 - 69 N=67 (%) |
Age ≥ 70 N=87 (%) |
P value* | |
| ECOG PS | ||||
| 0 - 1 | 247 (98.8) | 67 (100.0) | 85 (97.7) | 0.57 |
| 2 | 3 (1.2) | - | 2 (2.3) | |
| Hormone Receptor Status | ||||
| ER+ | 231 (92.8) | 63 (94.0) | 82 (94.3) | p=0.60 |
| PgR+ | 211 (84.7) | 58 (86.6) | 74 (85.1) | p=0.88 |
| Comorbidities | ||||
| Cardio-vascular | 70 (28.1) | 37 (55.2) | 41 (47.1) | 0.0001 |
| Metabolic | 40 (16.0) | 16 (23.8) | 18 (20.7) | 0.2180 |
| Gastrointestinal | 20 (8.0) | 3 (4.5) | 10 (11.5) | 0.4630 |
| Musculoskeletal | 11 (4.4) | 5 (7.5) | 11 (12.6) | 0.0082 |
| Others | 43 (17.3) | 20 (29.8) | 29 (33.3) | 0.0008 |
| Number of metastatic sites | ||||
| 1 | 173 (69.5) | 37 (55.2) | 61 (70.1) | p=0.72 |
| 2 | 61 (24.5) | 24 (35.8) | 21 (24.1) | |
| ≥ 3 | 15 (6.0) | 6 (8.9) | 5 (5.8) | |
| Metastatic sites | ||||
| Bone | 180 (72.3) | 46 (68.7) | 53 (60.9) | p=0.05 |
| Viscera | 75 (30.1) | 29 (43.3) | 30 (34.5) | p=0.25 |
| Soft tissue | 84 (33.7) | 25 (37.3) | 31 (35.6) | p=0.67 |
| Previous therapies – metastatic setting | ||||
| ET | 76 (30.5) | 26 (38.8) | 41 (47.1) | p=0.02 |
| CHT | 23 (9.2) | 5 (7.5) | 6 (6.9) | |
| ET - CHT | 150 (60.2) | 36 (53.7) | 40 (46.0) | |
| Number of prior ET – metastatic setting | ||||
| 1 | 170 (75.2) | 47 (75.8) | 57 (70.4) | P=0.48 |
| 2 | 51 (22.6) | 14 (22.6) | 22 (27.2) | |
| ≥ 3 | 5 (2.2) | 1 (1.6) | 2 (2.5) | |
| Number of prior CHT – metastatic setting | ||||
| 1 | 90 (52.0) | 21 (51.2) | 28 (60.9) | P=0.06 |
| 2 | 43 (24.9) | 10 (24.4) | 16 (34.8) | |
| ≥ 3 | 40 (23.1) | 10 (24.4) | 2 (4.6) | |
* Cochran-Mantel-Haenszel Statistics (Based on Table Scores) was used.
ET=endocrine therapy; CHT=chemotherapy.